Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 500680 | NSE Symbol : PFIZER | ISIN : INE182A01018 | Industry : Pharmaceuticals - Multinational |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
21-Feb-2025	21-Feb-2025	Others	Pursuant to the Regulation 30 of the Listing Regulations, we hereby inform that, the Board of Directors of the Company at their Meeting held today, that commenced on February 20, 2025 at 11.00 a.m. and concluded on February 21, 2025 at 1.45 p.m have approved a proposal today, to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane
24-Jan-2025	31-Jan-2025	Quarterly Results	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 inter alia to consider and approve Board Meeting to consider and take on record the Unaudited Financial Results for the quarter and nine months ended December 31 2024 Outcome of the Board Meeting- Unaudited Financial Results for the quarter and nine months ended December 31, 2024 (As Per BSE Announcement Dated on: 31/01/2025)
21-Oct-2024	28-Oct-2024	Quarterly Results	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve Unaudited Financial Results for the quarter and half year ended September 30 2024. Outcome of the Board Meeting-Unaudited Financial Results for the quarter and half year ended September 30, 2024 (As per BSE Announcement dated on: 28/10/2024)
22-Jul-2024	29-Jul-2024	Quarterly Results	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter ended June 30 2024. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results for the quarter ended June 30, 2024, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 4.00 p.m. and concluded at 7.25 p.m. Also please find enclosed the Limited Review Report by our Statutory Auditors, M/s. B. S. R. & Co., LLP, in respect of the said results Intimation pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure) Regulations, 2015. (As per BSE Announcement Dated on 29/07/2024)
06-May-2024	17-May-2024	Final Dividend	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve the Audited Financial Results of the Company for the Financial Year ended March 31 2024 and to consider recommendation of dividend if any for the Financial Year ended March 31 2024. The Board of Directors has at its Meeting held today, i.e., May 17, 2024, recommended a dividend of Rs. 35/- per equity share of Rs. 10/- each (350%) for the financial year ended March 31, 2024. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 6, 2024. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Audited financial results for the financial year ended March 31, 2024, Statement of Assets and Liabilities as on March 31, 2024, Statement of Audited Cash Flows for the year ended March 31, 2024, Declaration with respect to Audit Report with unmodified opinion and the Auditor''s Report by our Statutory Auditors, M/s. B S R & Co., LLP. The Audited financial results for the year ended March 31, 2024 were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 3:00 p.m. and concluded at 7:15 p.m (As Per NSE Announcement Dated on 17.05.2024) We refer to our letter dated May 17, 2024, informing you about the Audited Financial Results for the financial year ended March 31, 2024, Statement of Assets and Liabilities as on March 31, 2024, Statement of Audited Cash Flows for the year ended March 31, 2024 and Declaration with respect to unmodified opinion. We wish to bring to your notice that by oversight the Auditor''s Report was not attached with the said filing. Please find attached Auditor''s Report dated May 17, 2024, by our Statutory Auditors, M/s. B.S.R. & Co. LLP. Please note that there are no changes in the Audited Financial Results for the year ended March 31, 2024, published on May 17, 2024. Request you to please take the above on record. Read less.. (As Per BSE Announcement Dated on 27.05.2024)
31-Jan-2024	09-Feb-2024	Quarterly Results	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2024 inter alia to consider and approve and take on record the Unaudited Financial Results of the Company for the quarter ended December 31 2023. Pursuant to the Pfizer Limited - Code of Internal Procedures and Conduct to Regulate Monitor and Report Trading by Insiders the Trading Window of the Company was closed from December 31 2023 till 48 hours after the results are made public on February 9 2024. Request you to please take the above on record. Financial results for the quarter ended December 31, 2023. Re-appointment of Ms. Meena Ganesh (As Per BSE Announcement dated on 09.02.2024)
22-Jan-2024	22-Jan-2024	Change in Directors	Pursuant to Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby inform you that upon recommendation of the Nomination Remuneration Committee, the Board of Directors at their meeting held today appointed Mr. Amit Agarwal as the Chief Financial Officer and Executive Director - Finance of the Company effective February 26, 2024.
18-Oct-2023	28-Oct-2023	Quarterly Results	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2023 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Saturday October 28 2023 inter alia to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2023. Pursuant to the Pfizer Limited - Code of Internal Procedures and Conduct to Regulate Monitor and Report Trading by Insiders the Trading Window of the Company was closed from Saturday September 30 2023 till 48 hours after the results are made public on October 28 2023. Request you to please take the above on record. Pfizer Limited - Unaudited financial results for the quarter and half year ended September 30, 2023 Pfizer Limited Unaudited Financial Results - September 30 2023 (As Per BSE Announcement Dated on 28.10.2023)
04-Aug-2023	11-Aug-2023	Quarterly Results	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve and take on record the Unaudited Financial Results of the Company for the quarter ended June 30 2023. Pursuant to the Pfizer Limited - Code of Internal Procedures and Conduct to Regulate Monitor and Report Trading by Insiders the Trading Window of the Company was closed from Friday June 30 2023 (close of business) till 48 hours after the results are made public on August 11 2023. We request you to kindly take the same on record. Pfizer Limited - Unaudited Financial Results for the quarter ended June 30, 2023 (As Per BSE Announcement Dated on 11.08.2023)
05-May-2023	15-May-2023	Final Dividend	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2023 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday May 15 2023 inter alia to consider and take on record the Audited Financial Results of the Company for the Financial Year ended March 31 2023 and to consider recommendation of final dividend if any for the Financial Year ended March 31 2023. Pursuant to the Pfizer Limited - Code of Internal Procedures and Conduct to Regulate Monitor and Report Trading by Insiders the Trading Window of the Company was closed from Friday March 31 2023 (close of business) till 48 hours after the results are made public on May 15 2023. We request you to kindly take the same on record. Please be informed that the Board of Directors has at its Meeting held today, i.e., May 15, 2023, recommended a final dividend of Rs. 35/-per equity share of Rs. 10/- each (350%) and a special dividend of Rs. 5/- per equity share of Rs. 10/- each (50%) in view of the gain on sale of business undertaking at Thane, aggregating to total dividend of Rs. 40/- per equity share of Rs. 10/- each (400%) for the financial year ended March 31, 2023. The said final dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 16, 2023. (As per BSE Announcement Dated on 15/05/2023)
01-Feb-2023	09-Feb-2023	Quarterly Results	Quarterly Results PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 9, 2023, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended December 31, 2022. Pursuant to the 'Pfizer Limited - Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders', the Trading Window of the Company was closed from Saturday, December 31, 2022, till 48 hours after the results are made public on February 9, 2023. We request you to kindly take the above on record. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the third quarter and nine months ended December 31, 2022. The said results were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 2.45 p.m. and concluded at 4.30 p.m. Also please find enclosed the Limited Review Report by our Auditors M/s. B S R & Co., LLP, in respect of the above results. Please take the above on record. As required under Regulation 30 & 33 of SEBI (LODR) Regulations, 2015, please find enclosed herewith a copy of the Un-audited Financial Results (Standalone & Consolidated) of the Company for the Third Quarter & Nine months ended 31st December, 2022. Also, find enclosed herewith a copy of the Limited Review Report (LRR) (Standalone & Consolidated) dated 09th February, 2023, as issued by the Statutory Auditors of the Company viz. M/s. P A R K & Co. The said results have been approved and the LRR has been taken on record by the Board of Directors at its meeting held on 09th February, 2023. Further, pursuant to SEBI Regulations, 2015, we are enclosing herewith a Press Release being issued by the Company for the quarter ended 31st December 2022. These results & Press release are also being made available on the website of the Company at www.ashapura.com. The Meeting started at 12.00 Noon and concluded at 4.20 pm. Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby Inform you that the Board of Directors of the Company at their Meeting held today appointed Ms. Meenakshi Nevatia (DIN: 08235844) as an Additional Director and Managing Director of the Company for a period of 5 years with effect from April 3, 2023. The appointment of Ms. Nevatia will be subject to the approval of shareholders through Postal Ballot and Central Government. Additional details required to be disclosed pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and List/Comp/14/2018-19 dated June 20, 2018, are enclosed as Annexure A. (As Per BSE Announcement Dated on 09/02/2023)
03-Nov-2022	11-Nov-2022	Quarterly Results	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday November 11 2022 inter alia to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2022. Pursuant to the Pfizer Limited - Code of Internal Procedures and Conduct to Regulate Monitor and Report Trading by Insiders the Trading Window of the Company was closed from Friday September 30 2022 (close of business) till 48 hours after the results are made public on November 11 2022. We request you to kindly take the same on record. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter and half year ended September 30, 2022. The said results were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 2.15 p.m. and concluded at 4.00 p.m. Also please find enclosed the Limited Review Report by our Auditors M/s. B S R & Co., LLP, in respect of the above results. Please take the above on record (As Per BSE Announcement dated on 11.11.2022)
01-Sep-2022	06-Sep-2022	Interim Dividend	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2022 inter alia to consider and approve This is to inform you that a Meeting of Board of Directors of the Company is scheduled to be held on Tuesday September 6 2022 to consider declaration of Interim Dividend for the Financial Year ending March 31 2023. Further please be informed that Pursuant to the Pfizer Limited - Code of Internal Procedures and Conduct to Regulate Monitor and Report Trading by Insiders the Trading Window of the Company shall remain closed from Thursday September 1 2022 (close of business) till 48 hours after the declaration of Interim Dividend i.e. September 8 2022 (close of business). The Board of Directors at its meeting held today, i.e., September 6, 2022 has declared an Interim (Special) Dividend of Rs. 30/- per equity share of Rs. 10/- each (300%) for the financial year ending March 31, 2023, in view of the gain on account of sale of Upjohn Business to Mylan Pharmaceuticals Private Limited. The said Board Meeting commenced at 11.45 a.m. and concluded at 12.40 p.m. The said Interim Dividend will be paid to the eligible Members of the Company on or before Friday, September 30, 2022. We further inform you that the Record Date for the payment of aforementioned Dividend of Rs. 30/- (300%) per equity share is Tuesday, September 20, 2022. (As Per BSE Announcement Dated on 06.09.2022)
27-Jul-2022	05-Aug-2022	Quarterly Results	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2022 inter alia to consider and approve This is to inform you that a meeting of. the Board of Directors of the Company is scheduled to be held on Friday August 5 2022 inter alia to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30 2022. Pursuant to the 'Pfizer Limited - Code of Internal Procedures and Conduct to Regulate Monitor and Report Trading by Insiders' the Trading Window of the Company was closed from Thursday June 30 2022 (close of business) till 48 hours after the results are made public on August 5 2022. We request you to kindly take the same on record. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter ended June 30, 2022, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 12:00 noon and concluded at 2:45 p.m. Also please find enclosed the Limited Review Report by our Auditors M/s. Walker Chandiok & Co LLP, in respect of the above results. (As per BSE Announcement Dated on 05/08/2022)
10-May-2022	20-May-2022	Accounts	PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 inter alia to consider and approve a meeting of the Board of Directors of the Company is scheduled to be held on Friday May 20 2022 inter alia to consider and take on record the Audited Financial Results of the Company for the Financial Year ended March 31 2022 and to consider recommendation of dividend if any for the Financial Year ended March 31 2022. Pursuant to the 'Pfizer Limited - Code of Internal Procedures and Conduct to Regulate Monitor and Report Trading by Insiders' the Trading Window of the Company was closed from Thursday March 31 2022 (close of business) till 48 hours after the results are made public on May 20 2022. We request you to kindly take the same on record. The Board of Directors have at its Meeting held today, i.e., May 20, 2022, recommended a dividend of Rs. 35/- per equity share of Rs. 10/- each {350%) for the financial year ended March 31, 2022. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 23, 2022. Pursuant to Regulation 33 of the SEBI (Listing Obligation Disclosure Requirements) Regulations, 2015, we submit herewith audited financial results for the financial year ended March 31, 2022, Statement of Assets and Liabilities as on March 31, 2022, Statement of Audited Cash Flows for the year ended March 31, 2022, Declaration with respect to Audit Report with unmodified opinion and the Auditor''s Report by Auditors, M/s. Walker Chandiok & Co LLP, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 5.00 p.m. and concluded at 7.15 p.m. The Board of Directors have at its Meeting held today, i.e., May 20, 2022, recommended a dividend of Rs. 35/- per equity share of Rs. 10/- each {350%) for the financial year ended March 31, 2022. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 23, 2022. This is to inform you that the Statutory Auditors of the Company, M/s. Walker Chandiok & Co LLP would be completing their term of 5 years at the ensuing Annual General Meeting ofthe Company. Consequently, based on the recommendation of the Audit Committee of the Company, the Board of Directors ofthe Company at its meeting held today, i.e., May 20, 2022, recommended appointment of M/s. B S R & Co. LLP, Chartered Accountant (Firm Registration No. 101248W/W-100022) as the Statutory Auditors of the Company. Accordingly, M/s. BS R & Co. LLP will hold office for a period of 5 (five) consecutive years from the conclusion of the ensuing 71st Annual General Meeting of the Company till the conclusion of the 76th Annual General Meeting subject to the approval of the shareholders of the Company. (As Per BSE Announcement Dated on 20.05.2022) We refer to our letter dated May 20, 2022, wherein the Company had informed that, the Board of Directors of the Company at their Meeting held on May 20, 2022, had recommended appointment of M/s. B S R & Co. LLP, Chartered Accountant (Firm Registration No. 101248W/W100022) as the Statutory Auditors of the Company for a period of 5 (five) consecutive years from the conclusion of the ensuing 71st Annual General Meeting of the Company till the conclusion of the 76th Annual General Meeting subject to the approval of the shareholders of the Company. We enclosed herewith a brief profile of M/s. B S R & Co. LLP, Chartered Accountant. (As Per BSE Announcement dated on 23.05.2022)

1 2

LOGIN HERE

Pfizer Ltd

Board Meeting